Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gimatecan in Advanced/Metastatic Pancreatic Cancer
NCT04571489Phase 2Unknown
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gimatecan in pancreatic cancer (PC) (2 arms), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoint: Progression Free Survival at 24 months. Status: unknown.
02
Drugs
gimatecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04571489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04571489.